Next Article in Journal
Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)
Next Article in Special Issue
The Evolving Role of Radiofrequency Guided Localisation in Breast Surgery: A Systematic Review
Previous Article in Journal
Epigenetic Reprogramming of Tumor-Associated Fibroblasts in Lung Cancer: Therapeutic Opportunities
Previous Article in Special Issue
Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma
Article

Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry

1
Pediatric Translational Research Unit, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
2
Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
3
X-ZELL Biotech Pte Ltd., Singapore 069535, Singapore
4
Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
5
Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
6
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
7
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand
*
Author to whom correspondence should be addressed.
Academic Editors: Mary Bebawy and Michelle Hill
Cancers 2021, 13(15), 3775; https://doi.org/10.3390/cancers13153775
Received: 18 June 2021 / Revised: 22 July 2021 / Accepted: 26 July 2021 / Published: 27 July 2021
(This article belongs to the Special Issue Emerging Technologies in Cancer Diagnostics and Therapeutics)
Cancer cells can detach from a primary tumour and present in peripheral blood as circulating tumour cells, or in the widest sense, as circulating atypical cells (CAC). Although CAC are a promising biomarker for non-invasive cancer screening, they occur at very low frequency and their detection and characterization remains challenging. We here validated isolation and concentration of untouched CAC from spiked cancer cell blood samples and combined this with matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). This workflow was optimised to detect as little as six cancer cells per 5000 white blood cells. Future development of our workflow may cover a larger range of cancer types and further improvements to enable the use of MALDI-TOF MS as a cancer-screening platform in clinical settings.
Circulating atypical cells (CAC) are released from a primary tumour site into peripheral blood and are indicators of cancer metastasis. CAC occur at very low frequency in circulating blood, and their detection remains challenging. Moreover, white blood cells (WBC) are the major contaminant in enriched CAC samples. Here, we developed matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) as a novel CAC characterization platform. Main spectra profiles (MSP) of normal and cancer cells were generated by MALDI-TOF MS, and a cell-main spectra database was then compiled and analysed using the MALDI Biotyper software. Logarithmic scores accurately predicted distinct cell types. The feasibility of this workflow was then validated using simulated samples, which were prepared by 5000 WBC of three healthy individuals spiked with varying numbers (3, 6, 12, 25, 50, and 100) of lung, colon, or prostate cancer cells. MALDI-TOF MS was able to detect cancer cells down to six cells over the background noise of 5000 WBC with significantly higher predictive scores as compared to WBC alone. Further development of cell-MSP database to cover all cancer types sourced from cell lines and patient tumours may enable the use of MALDI-TOF MS as a cancer-screening platform in clinical settings in the future. View Full-Text
Keywords: cell main spectra; circulating tumour cell; MALDI-TOF; method development cell main spectra; circulating tumour cell; MALDI-TOF; method development
Show Figures

Graphical abstract

MDPI and ACS Style

Chiangjong, W.; Bhakdi, S.C.; Woramongkolchai, N.; Vanichapol, T.; Pongsakul, N.; Hongeng, S.; Chutipongtanate, S. Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry. Cancers 2021, 13, 3775. https://doi.org/10.3390/cancers13153775

AMA Style

Chiangjong W, Bhakdi SC, Woramongkolchai N, Vanichapol T, Pongsakul N, Hongeng S, Chutipongtanate S. Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry. Cancers. 2021; 13(15):3775. https://doi.org/10.3390/cancers13153775

Chicago/Turabian Style

Chiangjong, Wararat, Sebastian C. Bhakdi, Noppawan Woramongkolchai, Thitinee Vanichapol, Nutkridta Pongsakul, Suradej Hongeng, and Somchai Chutipongtanate. 2021. "Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry" Cancers 13, no. 15: 3775. https://doi.org/10.3390/cancers13153775

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop